Implementing COVID-19 Testing in Massachusetts Phased Reopening Plans

August 12, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 8/12/2020 12:00:00 PM 8/12/2020 1:00:00 PM Implementing COVID-19 Testing in Massachusetts Phased Reopening Plans

COVID-19 testing is a significant part of the answer to reopen our economy and our lives – and will remain crucial even after vaccines or therapies eventually become available. Municipalities, companies, universities, hospitals, school systems, and families want to know how and when they could implement testing or be tested so our society can reopen more fully and more confidently. Ideally, we want a highly reliable, rapid test that provides results in minutes. We hear it is taking 7+ days to get a test back due to the current surges in our country and it seems like test companies are way over capacity. How does the MassBio community implement testing? Is it even realistic now? What kind of testing should be implemented? We’ll hear from those who were on the forefront of implementing testing as part of their reopening strategy and get a pulse on how it is going. We’ll also address the shortfalls of current testing and offer strategies to undertake testing as a key component of your reopening plans.

Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only. 

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Webinar, click "live-stream" button to view

COVID-19 testing is a significant part of the answer to reopen our economy and our lives – and will remain crucial even after vaccines or therapies eventually become available. Municipalities, companies, universities, hospitals, school systems, and families want to know how and when they could implement testing or be tested so our society can reopen more fully and more confidently. Ideally, we want a highly reliable, rapid test that provides results in minutes. We hear it is taking 7+ days to get a test back due to the current surges in our country and it seems like test companies are way over capacity. How does the MassBio community implement testing? Is it even realistic now? What kind of testing should be implemented? We’ll hear from those who were on the forefront of implementing testing as part of their reopening strategy and get a pulse on how it is going. We’ll also address the shortfalls of current testing and offer strategies to undertake testing as a key component of your reopening plans.

Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only. 

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Co-Founder and CEO, Verve Therapeutics
Sekar Kathiresan is a preventive cardiologist who has made groundbreaking discoveries of cardioprotective genetic mutations, which confer resistance to cardiovascular disease. He is director of the Massachusetts General Hospital (MGH) Center for Genomic Medicine and the Ofer and Shelly Nemirovsky MGH Research Scholar, director of the Cardiovascular Disease Initiative at the Broad Institute, and professor of medicine at Harvard Medical School. Dr. Kathiresan’s research laboratory focuses on understanding the inherited basis for blood lipids and myocardial infarction and using these insights to improve preventive cardiac care. For his research contributions, he has been honored with a Distinguished Scientist Award from the American Heart Association and the 2018 Curt Stern Award from the American Society of Human Genetics. In tandem with his research, his clinical focus is the primary prevention of myocardial infarction in individuals with a family history of heart attack. He graduated summa cum laude with a B.A. in history from the University of Pennsylvania and received his M.D. from Harvard Medical School. Dr. Kathiresan completed his clinical training in internal medicine and cardiology at MGH and his postdoctoral research training in human genetics at the Framingham Heart Study and the Broad Institute.